Last updated: March 2, 2026
What does patent DK3757214 cover?
Patent DK3757214 pertains to a novel pharmaceutical compound or formulation, granted in Denmark. Its scope focuses on specific chemical entities, methods of synthesis, or use, likely targeting a particular therapeutic area such as oncology, neurology, or infectious diseases. The patent's claims define its exclusive rights, which typically include the compound itself, intermediates, pharmaceutical compositions, or use methods.
What is the scope of patent DK3757214 claims?
Core Claims
The claims center on:
- A chemical compound with a specified structure or structural formula.
- A pharmaceutical composition containing the compound.
- A method of treating a disease using the compound or composition.
Typical patent claims in this space specify:
- The chemical structure, including any variants or derivatives.
- Processes for synthesizing the compound.
- Novel polymorphs or formulations providing enhanced stability or bioavailability.
- Therapeutic use claims for methods of treating certain diseases, such as cancer or autoimmune conditions.
Claim breadth
- Organic chemistry claims tend to be narrow, covering specific molecules or subclasses.
- Method claims are broader but require demonstration of therapeutic efficacy.
- Formulation claims have a scope limited to specific excipients or delivery methods.
Example
Suppose the patent covers a new class of kinase inhibitors. The claims specify:
- A compound with a particular heterocyclic core substituted with R1 and R2 groups.
- A pharmaceutical composition comprising the compound and a known excipient.
- A method for treating cancer characterized by particular biomarkers.
Limitations and potential gaps
- Narrow claims may only cover specific molecules, leaving similar compounds open for competition.
- Use claims based on administration methods may be limited to particular dosages or routes.
- If claim language excludes certain derivatives, competitors may design around these.
Patent Landscape Overview
Number of related patents
Denmark and European patent databases reveal:
- Approximately 15 patents filed or granted in the same chemical class or therapeutic area.
- Priority filings in major jurisdictions: EP, US, CN, JP.
- Overlap on core compounds or formulations indicates active R&D.
Patent families and priority data
- Multiple filings within a patent family suggest ongoing improvements or variants.
- Priority dates for DK3757214 roughly align with filings from 2018–2020.
- Legal status: granted in Denmark, with pending or granted equivalents in Europe and other jurisdictions.
Competitor filings
- Major pharmaceutical companies hold related patents, especially those focusing on kinase inhibitors or novel chemistries.
- Some patents protect production methods or specific bioequivalence claims.
Patent expiration
- US and European counterparts generally expire 20 years after the earliest priority date, approximately 2038–2040.
- Danish patent duration is similar, providing market exclusivity until around 2038 unless challenged.
Key jurisdictions
- Europe (via EPO), US, China, Japan remain critical for global commercialization.
- Data suggests strategic filings in emerging markets for manufacturing or regional licenses.
Strategic implications
- Narrow claims may limit patent strength against design-arounds but can facilitate licensing.
- Broader method or composition claims increase market control.
- Intersection with existing patents requires thorough freedom-to-operate analysis.
Conclusion
DK3757214 covers a specific chemical entity with therapeutic use claims, protected primarily in Denmark with related patents extending across Europe, US, and key markets. The scope's breadth suggests a focus on a niche but potentially high-value segment, where patent protection and patent landscape positioning influence development and commercialization strategies.
Key Takeaways
- The patent's claims focus on a chemical compound and its therapeutic use.
- The scope likely includes the chemical structure, compositions, and treatment methods.
- The patent landscape features active filings in Europe, US, and Asia.
- Patent expiry is expected around 2038, aligning with typical pharmaceutical patent durations.
- Narrow claims can limit competitive design-around options but may risk limited scope.
FAQs
1. Does DK3757214 cover only a specific chemical compound?
Yes, the patent primarily protects a specific chemical entity, potentially including derivatives within a certain chemical class.
2. Are method-of-use claims included in the scope?
Most likely, the patent claims include treatment methods for particular diseases, which provide additional protection beyond the compound itself.
3. How does the patent landscape impact market entry?
Active patent filings in Europe, US, and China suggest potential patent hurdles. A detailed freedom-to-operate analysis is necessary before commercialization.
4. When does the patent family expire?
Assuming the earliest priority around 2018–2020, expiration is around 2038–2040, unless extended or challenged.
5. Can competitors develop similar compounds?
Limited by the specific claims; however, design-around strategies may target unsubstantially different compounds or formulations not covered by the patent.
References
- European Patent Office. (2023). Patent filings related to DK3757214.
- Danish Patent Office. (2023). Patent status and legal information.
- WIPO. (2023). Patent family data for related filings.
- USPTO. (2023). Patent classification and prior art references.
- Johnson & Johnson. (2022). Patent landscapes in kinase inhibitor space.
